Empagliflozin antidiabetic drugs

Jardiance - BI-10773 - BI10773 - BI 10773



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - SGLT2 inhibitors in all type of patients - glucose lowering for cardiovascular prevention in all type of patients

Kadowaki, 2013empagliflozinNA
Kadowaki , 2014empagliflozinNA
1275.9 ongoing empagliflozinadd-on linagliptin + METNA NCT01734785
Ridderstrale, 2014empagliflozinGlimepiride + METNA NCT01167881
DeFronzo, 2015empagliflozinlinagliptin (add-on MET)NA NCT01422876
Lewin, 2015empagliflozinlinagliptin (monotherapy)NA NCT01422876
EMPA-REG OUTCOME, 2015empagliflozinplacebo7020 (4687/2333) Confirmatory NCT01131676
EMPA-REG OUTCOMEempagliflozinplaceboNA NCT01131676
1245.29 ongoing empagliflozinplaceboNA NCT02182830
Ferrannini, 2013empagliflozinplaceboNA NCT00789035
EMPA-REG MONO (Roden) vs placebo, 2013empagliflozinplaceboNA NCT01177813
Kadowaki, 2015empagliflozinplaceboNA NCT01193218
Barnett, 2014empagliflozinplaceboNA NCT01164501
EMPA-REG PIO (Kovacs), 2013empagliflozinplacebo (add on MET+/-PIO)NA NCT01210001
99050 ongoing empagliflozinplacebo (add on MET+/-SU)NA NCT01257334
EASE-2 ongoing empagliflozinPlacebo (add-on INS)NA NCT02414958
Rosenstock DOUBLON ???, 2013empagliflozinplacebo (add-on INS)NA
Rosenstock (1245.49), 2014empagliflozinplacebo (add-on INS+/-MET)NA NCT01306214
Rosenstock, 2013empagliflozinplacebo (add-on MET)NA NCT00749190
Ross, 2015empagliflozinplacebo (add-on MET)NA e2012-000905-53
EMPA-REG MET (Haring), 2014empagliflozinplacebo (add-on MET)NA NCT01159600
Araki, 2015empagliflozinplacebo (add-on standard treatment)NA NCT01368081
1275.19 ongoing empagliflozinplacebo add-on linagliptinNA NCT02453555
1276.1 (bitherapy MET) ongoing empagliflozin + METMETNA NCT01719003



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons